Why Midi Health is expanding into 'hormone-informed skin care' with Chief Medical Officer Dr. Kathleen Jordan, MD

Midi Health is betting on topical skin care and body care as it diversifies its telehealth offerings to capture more women. “Women in midlife go through amazing changes with their hormones, … [and] our skin care needs actually change over time with our hormone evolution,” Dr. Kathleen Jordan, MD, chief medical officer of Midi Health, told Glossy. “I usually talk about [this care expansion] as ‘hormone informed skin care’ because that's really what the market's been lacking.”  That is, skin care that treats a variety of skin concerns that can develop in mid-life such as dryness, loss of collagen, hyperpigmentation, and acne.  “We saw patients for many years without having [skin-care] products, but what we saw was them struggling to get good products that were actually designed for them,” Dr. Jordan said. “We now see tens of thousands of women every week, and we actually hear from them. We hear their questions. We understand where they're struggling to get products that actually are meaningful [for their skin concerns], and then in response, we can develop products that actually help them.”  For Midi Health, this means offering prescription and OTC products with ingredients like estrogen, retinol, hydroquinone and tretinoin. In June, Midi expanded its skin-care selection to include topical copper peptides. According to Dr. Jordan, this is just the start for the company. Midi Health launched in 2021 and currently treats around 25,000 women per week. Oftentimes, this includes care for issues dismissed by the traditional medical industry, like fatigue, weight gain, mood and sleep disturbance, which can be treated with things like hormone replacement therapies or other OTC and prescription interventions.  Midi Health is privately held by its founders plus investors like Connie Britton, Brandi Chastain, Tory Burch, Amy Schumer, and Meghan Markle, as well as private equity firms like Google Ventures and Emerson Collective, plus a laundry list of tech execs including Sheryl Sandberg, the former COO of Meta, and Tekedra Mawakana, the co-CEO of Waymo. Midi Health was valued at $1 billion following a $100 million series D funding round in February.  Glossy West Coast correspondent Lexy Lebsack sat down with Dr. Jordan to discuss Midi Health’s skin- and body-care aspirations, the category’s role in telehealth in the future, and how Midi Health hopes to earn more market share.